{"id":19601,"date":"2026-09-28T05:13:53","date_gmt":"2026-09-28T08:13:53","guid":{"rendered":"https:\/\/rtmedical.com.br\/tmp-en-1790583232621\/"},"modified":"2026-09-28T05:13:59","modified_gmt":"2026-09-28T08:13:59","slug":"esophageal-cancer-tumor-location-survival","status":"publish","type":"post","link":"https:\/\/rtmedical.com.br\/en\/esophageal-cancer-tumor-location-survival\/","title":{"rendered":"Esophageal Cancer: Tumor Site Shifts Survival by Therapy"},"content":{"rendered":"

Tumor location in the esophagus changes the prognosis of squamous cell carcinoma<\/strong>, but the direction of that effect depends on the treatment: among patients treated with radiotherapy, upper-third tumors had the best survival, whereas among surgical patients it was lower-third tumors that fared best. That is the finding of a multicenter study of nearly 4,000 patients presented at the ASTRO 2026 annual meeting in Boston by Dashan Ai, MD, and colleagues from Fudan University Shanghai Cancer Center in China. The authors argue that primary tumor site should feed into individualized treatment planning and into future revisions of TNM staging.<\/p>\n

\"Linear
In irradiated patients, the upper third of the esophagus was the site with the best survival; in operated patients, the lower third. Photo: Pexels.<\/figcaption><\/figure>\n

What the ASTRO study found<\/h2>\n

The Shanghai group assembled two independent multicenter retrospective cohorts, both restricted to locoregional esophageal squamous cell carcinoma (ESCC) without distant metastasis. The radiotherapy cohort included 2,773 patients and the surgical cohort 1,153. In each, overall survival was compared across upper-, middle- and lower-third tumors using multivariable Cox regression adjusted for sex, age, stage, histologic grade and period of diagnosis. The results were then externally validated in the U.S. population-based SEER registry using records from 1973 to 2013.<\/p>\n

In the irradiated cohort, upper-third tumors had the best survival. Relative to them, a middle-third location carried a significantly higher risk of death (HR 1.260; p < 0.001), and a lower-third location a higher risk still (HR 1.514; p < 0.001). In the surgical cohort the pattern flipped: lower-third tumors showed a trend toward better survival than upper-third tumors (HR 0.726; p = 0.078), although the overall effect of location did not reach statistical significance in that group (p = 0.178). According to the authors, SEER validation confirmed both directions.<\/p>\n

The central conclusion is that the prognostic weight of location is modified by treatment modality. As the group put it, the best outcomes are seen in upper tumors treated with radiotherapy and lower tumors treated with surgery. They point out that location has been part of esophageal TNM since the 7th edition, yet no large multicenter dataset had tested whether its weight shifts between radiation-based and surgical approaches.<\/p>\n

How TNM defines the upper, middle and lower thirds<\/h2>\n

In the AJCC 8th edition, location is defined by the tumor epicenter, measured in centimeters from the incisors at endoscopy and confirmed on CT. The cervical esophagus runs from 15 to less than 20 cm; the upper thoracic segment from 20 to less than 25 cm (sternal notch to azygos vein); the middle thoracic from 25 to less than 30 cm (azygos to inferior pulmonary vein); and the lower thoracic from 30 to 40 cm, including the esophagogastric junction when the epicenter extends no more than 2 cm into the stomach. For squamous cell carcinoma, location and grade enter the pathologic stage groups for pT2-3 N0 tumors, an acknowledgement that site matters, if only coarsely.<\/p>\n

That anatomical split translates into concrete treatment choices. Cervical and upper-third tumors sit against the trachea, larynx and recurrent laryngeal nerves; a clear-margin resection often means pharyngolaryngoesophagectomy, with major functional morbidity. Definitive chemoradiation is therefore the standard in that segment. In the lower third, by contrast, esophagectomy (Ivor Lewis or McKeown) after neoadjuvant therapy is the usual strategy for operable patients. The Shanghai study suggests that this practical logic is also reflected in survival.<\/p>\n

Squamous versus adenocarcinoma: why the histology matters<\/h2>\n

Squamous cell carcinoma accounts for most esophageal cancers worldwide and dominates in East Asia, East Africa and South America, driven by tobacco, alcohol and very hot beverages, including the mate drunk in southern Brazil, Uruguay and Argentina, which IARC classifies as probably carcinogenic above 65 \u00b0C. Adenocarcinoma, linked to reflux, Barrett’s esophagus and obesity, predominates in North America and Western Europe and clusters in the lower third. In Brazil, the national cancer institute INCA estimates roughly 11,000 new esophageal cancer cases a year, with a heavy squamous component, especially in the south.<\/p>\n

This means the profile of the Chinese cohorts is closer to what Brazilian and Latin American services see than that of Western studies dominated by adenocarcinoma. At the same time, uneven access to high-volume esophageal surgery in the region makes definitive radiotherapy the only curative option for a meaningful share of patients, which raises the stakes of knowing for which sites it performs best.<\/p>\n

Implications for radiation oncology planning<\/h2>\n

For the radiation oncologist, the finding that middle- and lower-third tumors do worse with radiotherapy resonates with familiar planning problems. Middle-third tumors lie between the heart and lungs, where cardiac and pulmonary dose constraints limit coverage, and may require elective volumes that stretch from cervical to abdominal nodal stations. In the lower third, respiratory motion, gastric and hepatic dose and drainage to celiac and paracardial nodes add further complexity. Accurate GTV definition with endoscopy, endoscopic ultrasound and PET\/CT, and the 3 to 4 cm longitudinal CTV margins, follow the principles in our guide to target volume delineation in radiotherapy<\/a>.<\/p>\n

The study also revives the dose-escalation debate. The INT 0123 and ARTDECO trials found no benefit from doses above 50.4 Gy in definitive chemoradiation, and a Chinese phase 3 trial comparing 50 and 60 Gy reached a similar result. If location genuinely modifies response, site-defined subgroups could become candidates for distinct strategies, including salvage approaches like those discussed in our article on reirradiation planning and cumulative dose<\/a>. In the neoadjuvant setting, CROSS (41.4 Gy with carboplatin and paclitaxel) and NEOCRTEC5010 (40 Gy with vinorelbine and cisplatin, restricted to squamous histology) showed a survival gain from chemoradiation followed by surgery, and that is the context in which the authors call for prospective validation.<\/p>\n

There is also a parallel with the society’s recent guidance. ASTRO’s first bladder-preservation radiotherapy guideline<\/a> moves in the same direction of tailoring indications to tumor characteristics rather than stage alone, and precision radiotherapy, as in SBRT for oligometastatic disease<\/a>, depends on exactly this kind of stratification.<\/p>\n

Limitations and what still needs proving<\/h2>\n

The design is retrospective, and the two arms are not comparable with each other: irradiated and operated patients differ in age, comorbidity, tumor extent and treatment intent, and the study did not randomize modality. The cohorts are Chinese, with their own staging, chemotherapy and surgical conventions. SEER validation relies on a 1973 to 2013 window that spans decades of 2D and 3D radiotherapy before IMRT, routine PET\/CT and the CROSS standard, and the registry records chemotherapy use only incompletely. The effect in the surgical cohort sat at the edge of significance.<\/p>\n

The authors themselves acknowledge that it is unknown whether these patterns hold with contemporary chemoradiation regimens and minimally invasive surgery. For now, the message is a robust hypothesis rather than a change in practice: tumor location deserves a place in multidisciplinary discussions and in the next staging models for squamous cell carcinoma, but the choice between radiotherapy and surgery still rests on the patient, resectability and the team’s experience.<\/p>\n

Source:<\/strong> AuntMinnie<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

ASTRO 2026 study of 3,926 ESCC patients: upper-third tumors do best with radiotherapy, lower-third tumors with surgery. Site may enter TNM staging.<\/p>\n","protected":false},"author":1,"featured_media":19577,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"om_disable_all_campaigns":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"ngg_post_thumbnail":0,"_rt_cluster":"","fifu_image_url":"","fifu_image_alt":"","footnotes":""},"categories":[99],"tags":[],"class_list":["post-19601","post","type-post","status-publish","format-standard","has-post-thumbnail","category-radiotherapy"],"aioseo_notices":[],"rt_seo":{"title":"","description":"ASTRO 2026 study of 3,926 ESCC patients: upper-third tumors do best with radiotherapy, lower-third tumors with surgery. Site may enter TNM staging.","canonical":"","og_image":"","robots":"index,follow","schema_type":"Article","include_in_llms":true,"llms_label":"Tumor location and survival in esophageal squamous cell carcinoma (ASTRO 2026)","llms_summary":"Multicenter retrospective study presented at ASTRO 2026 (Dashan Ai, Fudan University Shanghai Cancer Center) of 2,773 irradiated and 1,153 surgical patients with locoregional esophageal squamous cell carcinoma. With radiotherapy, upper-third tumors had the best survival (middle third HR 1.260; lower third HR 1.514; p<0.001). With surgery, lower-third tumors trended better (HR 0.726; p=0.078). Validated in SEER 1973\u20132013. Authors propose adding tumor site to treatment planning and TNM.","faq_items":[],"video":[],"gtin":"","mpn":"","brand":"","aggregate_rating":[]},"_links":{"self":[{"href":"https:\/\/rtmedical.com.br\/en\/wp-json\/wp\/v2\/posts\/19601\/"}],"collection":[{"href":"https:\/\/rtmedical.com.br\/en\/wp-json\/wp\/v2\/posts\/"}],"about":[{"href":"https:\/\/rtmedical.com.br\/en\/wp-json\/wp\/v2\/types\/post\/"}],"author":[{"embeddable":true,"href":"https:\/\/rtmedical.com.br\/en\/wp-json\/wp\/v2\/users\/1\/"}],"replies":[{"embeddable":true,"href":"https:\/\/rtmedical.com.br\/en\/wp-json\/wp\/v2\/comments\/?post=19601"}],"version-history":[{"count":1,"href":"https:\/\/rtmedical.com.br\/en\/wp-json\/wp\/v2\/posts\/19601\/revisions\/"}],"predecessor-version":[{"id":19603,"href":"https:\/\/rtmedical.com.br\/en\/wp-json\/wp\/v2\/posts\/19601\/revisions\/19603\/"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/rtmedical.com.br\/en\/wp-json\/wp\/v2\/media\/19577\/"}],"wp:attachment":[{"href":"https:\/\/rtmedical.com.br\/en\/wp-json\/wp\/v2\/media\/?parent=19601"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/rtmedical.com.br\/en\/wp-json\/wp\/v2\/categories\/?post=19601"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/rtmedical.com.br\/en\/wp-json\/wp\/v2\/tags\/?post=19601"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}